Drug Trial Radar · NCT07172347
Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo
Last checked: Nov 19, 2026Latest source record: Jan 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Oct 31, 2025
Primary completion
Aug 30, 2027
Study completion Aug 30, 2027
Sponsor
- Lead sponsor
- Jiangsu vcare pharmaceutical technology co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Sep 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study
Conditions
- Non-segmental Vitiligo
Interventions
VC005 tabletsDrug
VC005 groups repeat administration for 52 weeks
VC005 Tablets PlaceboDrug
VC005 Placebo groups repeat administration for 52 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in facial vitiligo area score index (F-VASI) relative to baseline at week 24Time frame: Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Peking University People's Hospital
Beijing, Beijng, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.